The management of patients with stable coronary syndromes by Commerford, Patrick
32
Some may justifi ably argue that the management of patients with stable 
coronary disease is hardly a relevant topic at a national meeting of specialist 
cardiologists.  Given the ubiquity of the condition,  all health care professionals 
should be fully-informed and expert in its management.  The guidelines 
issued by a number of professional organizations around the world are 
clear and explicit and hardly require specialist training for implementation. 
Many are issued in extremely simple formats readily understandable by non-
medically trained persons. Indeed, much of the essential information about 
the life-style choices that may prevent the development of the condition 
or avert its devastating consequences is readily available in broadcast media, 
daily newspapers and popular magazines. 
This brief and admittedly incomplete review addresses only some issues 
of interest and importance.  There is some new information about the 
importance of risk factors and life-style choices that deserves emphasis. 
When considering medical treatment, appropriate use of established 
therapies is important and it is becoming clear that avoidance of some 
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commonly used medications may be important for patients with coronary 
disease.  Revascularization strategies are central to much current discussion 
and debate on how best to manage patients with the acute coronary 
syndromes.  There is still controversy on how or when it is best to advise 
revascularization for patients with stable symptoms.  
The Framingham data suggest that stable angina may be the presenting 
symptom in about 40% of all patients with coronary disease. (1) It is 
the management of those patients that is the focus of this discussion. 
Large clinical trials and meta-analyses of the results have resulted in the 
development of a considerable body of evidence that is available to 
clinicians and patients to guide risk stratifi cation and therapeutic choices 
in the acute coronary syndromes.  There is much less good information 
available to guide our choices in patients with stable coronary syndromes.
SYMPTOMS  AND PROGNOSIS IN CORONARY         
DISEASE 
In some diseases, symptoms and prognosis are closely linked.  Patients 
who feel sick die and those who feel well do not.  In coronary disease, 
there is an unfortunate disconnect between symptoms and prognosis. 
The Framingham data is congruent with everyday experience.  Sudden 
unexpected death or devastating acute myocardial infarction with signifi cant 
residual disability may be the fi rst manifestation of the disease.  Conversely, 
patients with chronic stable angina, managed appropriately, may have a 
good prognosis and excellent quality of life.
Patients with stable angina are rightly concerned that the coronary stenosis 
causing their symptoms may progress to cause myocardial infarction or 
death and will welcome any intervention to remove the stenosis in the 
mistaken belief that the intervention relieving symptoms will also improve 
prognosis.  We now know that this is not correct and this knowledge should 
infl uence our practice and the information we give our patients.
There are several contemporary reports of a surprisingly good prognosis 
in patients with established coronary disease and stable symptoms when 
managed medically.  The annual incidence of death is between 1-2% and 
the incidence of myocardial infarction is similar. (2,3)  Treated appropriately, 
stable angina is a condition with a reasonable prognosis in the majority 
of middle-aged or older patients in which it occurs.  The challenge is to 
ensure that our treatments optimize survival and do not impact adversely 
on it.  Recent trials of revascularization compared to medical treatment in 
stable angina confi rm the relatively benign prognosis of patients treated 
medically.  In some the prognosis on medical treatment was better than 
in those treated by percutaneous revascularization. (4) In my view, there is 
insuffi cient published evidence to support the performance of percutaneous 
intervention (PCI) in patients with chronic stable angina for any reason 
other than relief of symptoms of angina.  The views of some practitioners 
Corresponding author
Professor PJ Commerford
Cardiac Clinic, Department of Medicine
University of Cape Town and Groote Schuur Hospital
Anzio Road, Observatory
Cape Town, 7925
Email: pjcomfrd@uctgsh1.uct.ac.za
Authors: Patrick Commerford MBchB, FCP (SA), FACC
  In coronary artery disease, symptoms and 
prognosis are not closely linked and sudden unexpected death or 
devastating acute myocardial infarction may be the fi rst manifestation. 
In treating patients with stable coronary disease, we wish to both 
relieve symptoms and prevent adverse outcomes. Percutaneous 
revascularization provides excellent symptom relief but has no 
positive prognostic benefi t in patients with stable coronary disease. 
The lesion causing the angina, treated by a stent, is not necessarily the 
lesion determining prognosis.  Simple lifestyle modifi cation and drug 
therapy are important determinants of prognosis. Coronary bypass 
graft surgery improves prognosis in well-defi ned subsets of patients 
and the application of percutaneous interventions in patients who 
might be better served by surgery can be questioned.  It can be 
argued that the emphasis placed on percutaneous intervention in 
patients with stable disease may have adverse consequences.    
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and patients that PCI improves prognosis or averts future adverse events 
are not supported by the available evidence. When the risks of the disease 
are low and any intervention carries a small but defi nite risk of harm, the 
choice of therapy to infl uence prognosis positively becomes diffi cult.  The 
issue remains unsettled and the results of the COURAGE trial, which 
compares intensive medical therapy to a strategy of PCI plus intensive 
medical therapy, are eagerly awaited.5
IS RISK FACTOR MODIFICATION USEFUL?                 
The value of risk factor modifi cation and the magnitude of its impact on 
prognosis sometimes is lost in the argument as to whether or how best 
patients should be revascularized. Although never formally tested against 
revascularization, the magnitude of prognostic benefi t of effective risk factor 
intervention arguably exceeds many of our medical interventions.
The INTERHEART study confi rmed that smoking was an extremely 
important risk factor for myocardial infarction in Africa, showed that all 
forms of tobacco use were harmful, that there was a clear dose-effect 
relationship and that second-hand smoke was harmful. (6) 
There is now overwhelming evidence of the harmful effects of second-
hand smoke . (7,8) Smoking cessation and avoidance may be the single most 
powerful intervention we can offer in terms of improving prognosis. How 
much time and effort do we devote to this, compared to the time spent in 
the catheterization laboratory?
Exercise training improves symptoms in patients with coronary disease. 
Training shifts the heart rate / oxygen consumption curve to the right. 
Work elicits a slower heart rate response and the onset of angina is 
delayed. (9)   There is admittedly limited, but nonetheless intriguing, information 
suggesting that exercise may offer greater prognostic benefi t than PCI in 
stable patients.  In a small trial which randomized stable male patients with 
coronary lesions eligible for PCI to intervention or an exercise program 
combined with regular counseling, event-free survival was better in those 
treated conservatively. (10) 
Advice and encouragement to modify lifestyle seem all too often to be an 
afterthought and are considered by both practitioners and patients as of 
lesser importance than the apparently potent scientifi c and technological 
interventions of drugs and devices.  The reality is sobering.  Whereas PCI 
has no proven positive impact on prognosis in stable coronary disease, life-
style changes may have an effect at least as great as and possibly greater 
than many of the commonly prescribed pharmacological interventions that 
are of proven benefi t. (11) 
PHARMACOLOGICAL THERAPY                                   
This is not intended to be a comprehensive review of drug therapy, but 
rather a discussion of some aspects, particularly as they may infl uence 
prognosis.
Aspirin is well established and widely and appropriately used in most 
patients with coronary disease.  The prognostic benefi ts are greatest in 
patients at highest risk (those who have recently suffered an acute coronary 
syndrome) and may be much less in stable patients in whom the bleeding 
risk may closely approximate the benefi t in terms of vascular events 
avoided. (12) Bleeding risk is related to dose and low-dose aspirin is not 
generally available in the state sector in South Africa, with the consequence 
that the standard prescription is 150mg, which is double the lowest effective 
daily dose.12  This may be particularly harmful in Africa where Helicobacter 
pylori positivity is more common than in Europe and North America. 
The benefi t of secondary prevention with statins is clearly established.  The 
inordinate delay in making them available for treatment and restrictions on 
dose-levels in some regions of the state sector (the Western Cape) may 
have been driven by cost. Despite recent reductions in price, patients in 
private practice often fi nd it diffi cult to maintain treatment for prolonged 
periods of time. 
However, any reduction in LDL-cholesterol is better than none (13) and 
even the very low doses available in some public-sector hospitals do have 
a benefi cial effect and patients should be encouraged to persevere.
The long-term protective effect of the angiotensin converting enzyme 
inhibitors (ACE-Is) in stable patients are well-established. (14,15) Generic 
agents are now readily available, but are surprisingly infrequently used in 
patients with angina who meet the criteria as defi ned in the trials which 
showed prognostic benefi t.  The reasons for this underutilization are unclear. 
At least partly it may be due to aggressive marketing of the angiotensin 
receptor blockers, which as yet lack evidence for similar protective benefi t.
Beta-blockers offer very effective relief of symptoms and have been 
considered to offer prognostic benefi t compared to calcium channel 
blockers in uncomplicated patients with stable angina, but there is no 
good evidence supporting this opinion. (16) They clearly do offer prognostic 
benefi t in heart failure and after myocardial infarction and, therefore, should 
be part of the therapy of all such patients unless contraindicated.
In addition to utilizing agents that improve prognosis, it is essential to avoid 
those that may cause harm.  The increased vascular risk associated with 
the use of selective cyclooxygenase-2 inhibitors is well established and 
has resulted in the withdrawal of some of these agents.  Whether similar 
risk attaches to the use of nonselective nonsteroidal anti-infl ammatory 
drugs (NSAIDs) is unclear, but worrying, given their widespread and 
indiscriminate use.  They are freely available over the counter, used for a 
variety of non-specifi c aches and pains and are often prescribed at the 
patients request without a good indication.  A recent report that NSAIDs 
in high dose increase mortality in patients with previous myocardial 
infarction is concerning. (17)  The number needed to treat to cause harm 
is disturbingly low and it seems prudent to advise caution in prescribing 
these agents to patients with vascular disease and to ensure that they are 
only used for valid indications. It is sobering to consider that in some state 
sector facilities it is easier to prescribe NSAIDs (which may cause harm) 
than statins (which defi nitely result in benefi t) for patients with angina. 
REVASCULARIZATION IN STABLE ANGINA: WHEN 
AND HOW?
All revascularization strategies provide superior symptomatic relief when 
compared to medical therapy. Any controversy that exists relates to 
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prognosis in patients with mild or controlled symptoms. Doctors and 
patients seem to believe that PCI and stents, in particular, offer prognostic 
benefi t.  The majority of patients referred to my clinic report that they 
have been told they can have a “little spring” put in “from outside” and that 
this will protect against future heart attack, death, disability and the need 
for coronary bypass surgery!  The reality for patients with stable angina is 
somewhat different.
Coronary artery bypass graft surgery (CABG) was shown to offer 
prognostic benefi t when compared to medical therapy in a series of 
trials. (18) Mortality benefi t was proportional to baseline risk and, though 
small, was defi nitely present.  In contrast, a meta-analysis of trials comparing 
PCI to medical therapy in nonacute coronary artery disease failed to 
show any benefi t in terms of death, myocardial infarction, or the need 
for subsequent revascularization. (19) Two analyses of revascularization in 
patients with stable disease concluded that CABG resulted in lower fi ve- 
year mortality, less angina and a reduced need for repeat revascularization 
compared with PCI. (20,21) Analysis of a large non-randomized database 
in real-world practice showed that CABG offers a survival advantage to 
patients with disease involving two or more coronary arteries. (22) At least 
part of the reason may be that CABG successfully treats both the lesion 
causing the angina and, unlike PCI, provides an alternative conduit bypassing 
minor asymptomatic lesions, which are the determinants of future adverse 
events. (23) These considerations lead one to question why patients with 
symptoms and anatomy known to benefi t from CABG are still submitted 
to PCI (13) and to question why patients with minimal symptoms are treated 
by PCI before an adequate trial of medical therapy.  An improvement in 
quality of life is often cited, but the available evidence suggests that PCI may 
result in worsening of measures of quality of life in patients who do not 
have bad symptoms. (24)
The popularity of PCI and its ready acceptance by patients with stable or 
minimal symptoms is surprising and presumably is based on a mistaken 
belief that it improves prognosis, is safe and free of complications.  The latter 
is far from true.  While technological advances and operator skill result in 
superb angiographic results in the majority of patients, there is a defi ned risk 
associated with PCI.  The published results from large real-world registries 
of usual practice indicate that the short-term risks are not negligible. (25,26) 
Patients and practitioners sometimes view PCI as a “holding” procedure, 
which delays CABG and there is a defi nite increase in the need for repeat 
revascularization, often by CABG, in patients initially treated by PCI.  There 
is at least one observational study suggesting disturbingly that prior PCI 
may increase (double) in-hospital mortality after CABG. (27) 
DRUG-ELUTING STENTS                                                 
Widespread optimism that the drug-eluting stents (DES) would make a 
signifi cant impact on prognosis has been proven to be unfounded.  The 
most recent four-year follow-up of comparisons of both CYPHER and 
TAXUS to bare metal stents show no difference in the incidence of the 
hard end-points of total mortality and myocardial infarction. (28) Those 
analyses were prompted by suggestions of excess mortality due to stent 
thrombosis in patients treated with DES in the BASKET trial.  These results, 
controversial as they are and as yet unpublished, are a major cause for 
concern and should prompt re-evaluation of everyday practice. (29)
The necessity of prolonged dual antiplatelet therapy to prevent stent 
thrombosis is problematic at best in an older patient population who 
may require non-cardiac surgery in the weeks and months after PCI. 
Compliance with expensive medication is diffi cult in our population and 
clopidogrel may be discontinued because of a patient’s inability to afford it, 
or else at the whim of hospital or medical aid administrators.  Inappropriate 
placement of a DES in a lesion causing minimal symptoms may convert 
an angiographic blemish into a fatal occlusion. Prior to valve replacement 
surgery, cardiologists spend a considerable amount of time determining 
whether patients are likely to be compliant with warfarin therapy, as this 
determines valve choice and long-term success.  Similar careful screening is 
probably necessary before deciding on placement of a DES, but is diffi cult 
amid the pressures of an invasive procedure.
CONCLUSION                                                                    
Simple lifestyle modifi cation and drug therapy offer signifi cant prognostic 
benefi t to patients with stable angina.  The advances in PCI technology offer 
dramatic symptomatic benefi t to those whose symptoms are not tolerable, 
but this is not accompanied by any improvement in prognosis. In stable 
angina, the prognosis is such that it is hard to justify an invasive procedure 
that does not offer prognostic benefi t, unless symptoms warrant it. 
There are three concerns that can be raised about the emphasis placed 
on percutaneous revascularization in stable angina. The fi rst relates to 
the diversion of resources. So much energy, enthusiasm and money is 
expended on a procedure that offers no prognostic benefi t, that both in 
the public hospitals and in the private sector, individual patients’ fi nancial 
resources, medical aid resources and public hospital budgets may be 
exhausted to the extent that prognostically benefi cial procedures, including 
CABG, may not be possible when they are truly needed.  The second is 
a diversion of the patient’s attention.  Performance of PCI has become 
such a routine, sometimes almost outpatient procedure that patients do 
not appreciate the signifi cance of their disease. They leave hospital thinking 
they are “cured” and return to unhealthy lifestyles in the mistaken belief that 
modern technology will rescue them again in future if it becomes necessary. 
The third is diversion of clinical attention.  Any symptom vaguely suggestive 
of angina leads in some practitioners’ hands to coronary angiography. 
Coronary angiography will inevitably reveal coronary stenoses in some 
patients, particularly in an older population.  Percutaneous intervention may 
well be performed on such incidentally discovered angiographic blemishes 
in the mistaken belief they are responsible for the presenting symptom. 
Delay in the diagnosis and treatment of the true cause of the symptoms 
may ensue.  
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